CONTEXT: MR imaging enhanced with ultrasmall superparamagnetic iron oxide (USPIO) particles can noninvasively monitor the behavior of novel anti-angiogenesis drugs, according to researchers at the University of Munster in Germany. The group is investigating USPIO-enhanced MR measurements of vascular volume fraction as a surrogate marker for tumor angiogenesis. Results, compiled by Dr. Thorsten Persigehl and colleagues at the university's Institute for Clinical Radiology, were summarized in a scientific poster at the European Congress of Radiology in March.
RESULTS: Tumor-bearing mice were treated intravenously with either an agent inducing thrombosis in selective tumor vasculature (11 mice) or saline (13 mice). All animals underwent MR imaging at 1.5T with a long-circulating USPIO (SHU 555C, Schering) four to eight hours after treatment. USPIO-induced changes to relaxation ( delta R2*) to determine the vascular volume fraction were measured using a T2-weighted dual echo-planar MR sequence.
Parametric delta R2* maps revealed a noticeable reduction in tumor perfusion in the treatment group compared with controls. This change was observed as early as four hours after injection with the anti-angiogenesis agent. Histological analysis confirmed the MR findings, showing extensive tumor thrombosis in the treatment group.
IMPLICATIONS: The study confirmed that USPIO-enhanced MR imaging measures early tumor response to anti-angiogenesis treatment, according to Persigehl. Radiologists will readily adopt this class of MR contrast media when it is introduced for clinical use, he said.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.